Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19920792 | 0.88 | SLC6A2 (0.31) | OPRD1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL27699520 | 0.84 | — | — | |
| SCHEMBL10916513 | 0.83 | SLC6A4 (0.34) | OPRD1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL29905540 | 0.79 | — | — | |
| SCHEMBL29614428 | 0.76 | OPRD1 (0.34) | OPRD1OPRM1 | |
| SCHEMBL5377836 | 0.76 | — | — | |
| SCHEMBL11552775 | 0.74 | ALDH1A1 (0.37) | SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL1856620 | 0.74 | — | — | |
| SCHEMBL232544 | 0.74 | — | — | |
| SCHEMBL7720694 | 0.73 | SLC6A2 (0.38) | OPRD1OPRM1SLC6A2SLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103333156-B | Preparation method of 2-substituted arylethenyl-N-methylated quinoline derivative and application of 2-substituted arylethenyl-N-methylated quinoline derivative in preparation of drug for treating Alzheimer disease | UNIV SUN YAT SEN | 2015-03-11 | — | — | CN | claimed |
| CN-103333156-A | Preparation method of 2-substituted arylethenyl-N-methylated quinoline derivative and application of 2-substituted arylethenyl-N-methylated quinoline derivative in preparation of drug for treating Alzheimer disease | UNIV ZHONGSHAN | 2013-10-02 | — | — | CN | claimed |
| US-12559593-B2 | Dual cure sealants | PRC-DESOTO INTERNATIONAL, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | EAGLE BIOLOGICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4272763-A2 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | Eagle Biologics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230242710-A1 | Dual Cure Sealants | PRC-DESOTO INTERNATIONAL, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-3043772-B1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11655340-B2 | Dual cure sealants | PRC-DESOTO INTERNATIONAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11471479-B2 | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents | EAGLE BIOLOGICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-110719928-B | Dual cure sealant | PRC-迪索托国际公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-111202711-B | Liquid protein formulations comprising organophosphates | 伊戈尔生物药品股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-10-30 | — | — | US | disclosed |
| EP-1349841-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1349840-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | disclosed |
| US-20030004159-A1 | Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-01-02 | — | — | US | disclosed |
| WO-2002083678-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083682-A1 | NOVEL 10-CYCLOHEXENYL-PHENYL PYRROLOBENZODIAZEPINE-3-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11471479-B2 | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents | RNGTT, SNRPA, SNRNP200 | OPRD1 3459/4885OPRM1 3020/4885SLC6A2 2428/4885 |
| US-11819550-B2 | Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP) | PDE7A, PDE8A, PDE8B | OPRD1 4404/4885OPRM1 4000/4885SLC6A2 2704/4885 |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | OPRD1 9/4885OPRM1 45/4885SLC6A2 2731/4885 |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | OPRD1 1817/4885OPRM1 3333/4885SLC6A2 4826/4885 |
| US-12559593-B2 | Dual cure sealants | DUOX2, DUOX1, GPX4 | OPRD1 312/4885OPRM1 709/4885SLC6A2 4244/4885 |
| US-20030004159-A1 | Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | OPRD1 10/4885OPRM1 49/4885SLC6A2 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.